Ionis Pharmaceuticals Inc

Latest Results (07.08.2024):

Revenue Growth

Ionis Pharmaceuticals Inc. reported a significant increase in revenue for the second quarter of 2024, reaching $225 million, up from $188 million in the same period last year. This 20% growth was primarily driven by an increase in research and development (R&D) revenue, reflecting the value generated by Ionis' pipeline and technology.

Operating Expenses

Operating expenses for Ionis Pharmaceuticals Inc. increased in the second quarter of 2024 to $291 million, compared to $279 million in the same period last year. This rise is attributed to continued strategic investments in late-stage development and commercialization efforts for key products like WAINUA, olezarsen, and donidalorsen.

Commercial Revenue

Ionis Pharmaceuticals Inc.'s commercial revenue for the second quarter of 2024 included $57 million from SPINRAZA royalties and $4 million from WAINUA royalties. The launch of WAINUA in the U.S. in late January 2024 contributed to this new source of royalty revenue.

R&D Revenue

Research and development revenue for Ionis Pharmaceuticals Inc. in the second quarter of 2024 was $153 million, up from $110 million in the same period last year. This increase was driven by the amortization of upfront payments from new collaborations with Roche and Novartis, as well as increased license fees from new collaborations.

Cash Position

As of June 30, 2024, Ionis Pharmaceuticals Inc. reported cash, cash equivalents, and short-term investments totaling $2.1 billion, down from $2.3 billion at the end of 2023. The company plans to continue deploying its capital resources toward growth opportunities and projects to end 2024 with a strong financial position.